As of March 31, 2026, Synthetic Biologics Inc (SYN) reports a Gross Margin of 85.44%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Synthetic Biologics Inc's Gross Margin to Peers
To better understand Synthetic Biologics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Synthetic Biologics Inc (SYN) | 85.44% |
| Aprea Therapeutics Inc (APRE) | 7775.20% |
| Neurobo Pharmaceuticals Inc (NRBO) | 7775.20% |
| Lumos Pharma Inc (LUMO) | 7775.20% |
| CohBar Inc (CWBR) | 7775.20% |
| Monopar Therapeutics Inc (MNPR) | 7775.20% |
Compared to its competitors, Synthetic Biologics Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.